Docetaxel-ifosfamide combination chemotherapy in patients with metastatic hormone-refractory prostate cancer: a phase I pharmacokinetic study.

@article{Hervonen2003DocetaxelifosfamideCC,
  title={Docetaxel-ifosfamide combination chemotherapy in patients with metastatic hormone-refractory prostate cancer: a phase I pharmacokinetic study.},
  author={Petteri Hervonen and Antti Jekunen and Patricia Lefebvre and Pirkko Kellokumpu-Lehtinen},
  journal={International journal of clinical pharmacology research},
  year={2003},
  volume={23 1},
  pages={1-7}
}
This phase I study was designed to evaluate the activity toxicity and pharmacokinetics of docetaxel combined with ifosfamide in the treatment of hormone-refractory prostate cancer. Ten patients received a median of 4.6 treatment cycles. Docetaxel was administered at a dose of 40 mg/m2 in a 1-hour infusion followed by ifosfamide 3,000 mg/m2 in a 24-hour infusion every 3 weeks. The optimal sequence of chemotherapeutic agents was investigated by reversing the order of administration in the second… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
0 Extracted Citations
0 Extracted References
Similar Papers

Similar Papers

Loading similar papers…